Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC).
11611 Background: DLL3 is highly expressed in tumor-initiating cells (TIC) in small cell lung cancer (SCLC), where the DLL3-targeted ADC rovalpituzumab tesirine (Rova-T; SC16LD6.5) is able to eradicate TIC in patient-derived xenografts (PDXs; Saunders et al. [2015] Sci Transl Med 7:302ra136) and exert clinically meaningful antitumor effects in SCLC patients (NCT01901653). Based on data in The Cancer Genome Atlas, melanoma, glioblastoma and other high-grade NECs may also have elevated DLL3 expression. Methods: DLL3 expression was profiled by qRT-PCR, ELISA and immunohistochemistry, where positivity was defined as > 1% of tumor cells with staining of any intensity. PDXs from melanoma and extrapulmonary NECs were established and the ability of Rova-T to impact tumor growth, TIC frequency and recurrence was assessed. Results: DLL3 expression was confirmed in metastatic melanoma (~50%), glioblastoma (~71%), medullary thyroid (~64%) and neuroendocrine pancreatic cancer (~20%) – the latter correlating with grade. Adrenal, neuroendocrine prostate and gastrointestinal tumors were also noted to be positive. With the exception of melanoma, where DLL3 expression inversely correlated with outcome, DLL3 expression significantly correlated with that of the ASCL1 transcription factor – a known driver of neuroendocrine tumorigenesis. In DLL3-expressing melanoma PDX tumor-bearing mice, a single dose of Rova-T halted tumor growth with no recurrences noted for > 120 days, and was accompanied by a significant reduction in TIC. Conclusions: DLL3 is expressed in a large proportion of melanoma, glioblastoma and other high-grade extrapulmonary NEC types. Treatment of DLL3-positive extrapulmonary PDX tumor-bearing mice with Rova-T resulted in effective and durable responses. Given encouraging clinical data with Rova-T in SCLC, clinical evaluation of Rova-T in DLL3-positive melanoma, glioblastoma, medullary thyroid and other high-grade neuroendocrine carcinomas is warranted. A “basket” trial enrolling patients with DLL3-positive solid tumors has been initiated.